Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, ewing

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Aug 2024: Trial registered, NCT06571734
  2. 19 Sep 2024: Trial started, NCT06571734

The trials

NCT06571734: XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

State
Under way
Phase
Phase 2
People
73 planned
Started
19 Sep 2024
Primary completion
1 Jul 2028
Arms
Treatment (XL092)
Results
None posted
  1. 26 Aug 2024: Trial registered
  2. 19 Sep 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.